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Metastatic Infectious Disease and Clinical Outcome in
Staphylococcus aureus and Streptococcus species Bacteremia
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Arie P. J. van Dijk, MD, PhD, Geert J. A. Wanten, MD, PhD, Wim J. G. Oyen, MD, PhD,
and Chantal P. Bleeker-Rovers, MD, PhD
Abstract: Early detection of metastatic infection in patients with Gram-
positive bacteremia is important as morbidity and mortality are higher
in the presence of these foci, probably due to incomplete eradication of
clinically silent foci during initial treatment. We performed a prospective
study in 115 patients with Staphylococcus aureus or Streptococcus spe-
cies bacteremiawith at least 1 risk factor for the development of metastatic
foci, such as community acquisition, treatment delay, persistently positive
blood cultures for 948 hours, and persistent fever 972 hours after initiation
of treatment. An intensive search for metastatic infectious foci was per-
formed including 18F-fluorodeoxyglucose-positron emission tomography
in combination with low-dose computed tomography scanning for opti-
mizing anatomical correlation (FDG-PET/CT) and echocardiography in
the first 2 weeks of admission.
Metastatic infectious foci were detected in 84 of 115 (73%) patients.
Endocarditis (22 cases), endovascular infections (19 cases), pulmonary
abscesses (16 cases), and spondylodiscitis (11 cases) were diagnosed
most frequently. The incidence of metastatic infection was similar in
patients with Streptococcus species and patients with S. aureus bacter-
emia. Signs and symptoms guiding the attending physician in the diag-
nostic workup were present in only a minority of cases (41%). An
unknown portal of entry, treatment delay 948 hours, and the presence of
foreign body material were significant risk factors for developing meta-
static foci. Mean C-reactive protein levels on admission were significantly
higher in patients with metastatic infectious foci (74 vs. 160 mg/L).
FDG-PET/CT was the first technique to localize metastatic infec-
tious foci in 35 of 115 (30%) patients. As only a minority of foci were
accompanied by guiding signs or symptoms, the number of foci revealed
by symptom-guided CT, ultrasound, and magnetic resonance imaging
remained low.
Mortality tended to be lower in patients without complicated infec-
tion compared to those with metastatic foci (16% vs. 25%, respectively).
Five of 31 patients (16%) without proven metastatic foci died. In retro-
spect, 3 of these 5 patients likely had metastatic foci that could not be
diagnosed while alive. In patients with Gram-positive bacteremia and a
high risk of developing complicated infection, a structured protocol in-
cluding echocardiography and FDG-PET/CT aimed at detecting meta-
static infectious foci can contribute to improved outcome.
(Medicine 2012;91: 86Y94)
Abbreviations: CI = confidence interval, CRP = C-reactive protein,
CT = computed tomography, FDG-PET/CT = 18F-fluorodeoxyglucose-
positron emission tomography in combination with low-dose computed
tomography, MRI = magnetic resonance imaging, TEE = transesopha-
geal echocardiography, TTE = transthoracic echocardiography.
INTRODUCTION
A n important complication of Gram-positive bacteremia isthe presence of complicating metastatic infectious foci both
by hematogenous and local spreading beyond the anatomic boun-
daries of the primary source of infection. Reported incidence of
complicating foci varies between 16% and 36%.8,9,15,17,20,26
Early detection of metastatic foci is important as morbidity and
mortality are higher in the presence of these foci, probably due to
incomplete eradication during initial treatment.17 However, me-
tastatic foci are often asymptomatic. In up to one-third of patients
with Gram-positive bacteremia and metastatic foci, localizing
signs and symptoms are absent.7 In a Danish study, more than
half of all patients admitted with Staphylococcus aureus spon-
dylodiscitis had no symptoms suggesting this diagnosis at the
time of admission.16
Treatment delay and community acquisition (which is
probably a surrogate marker of delayed treatment) are the most
important risk factors for the development of metastatic infec-
tion.9,10,24 Persistently positive blood cultures and fever despite
appropriate antibiotic treatment have a predictive value for the
presence of such complicating foci.9,22 It has been suggested that
an intensive search for the presence of metastatic foci reduces
relapse rates of infection and mortality.18 However, conventional
radiologic techniques would require the presence of guiding
symptoms as only a fixed part of the body is visualized. Nuclear
imaging techniques, such as whole body 18F-fluorodeoxyglucose-
positron emission tomography in combination with low-dose
computed tomography scanning for optimizing anatomical
correlation (FDG-PET/CT), might overcome this problem.28,29
FDG-PET/CT is able to visualize localized foci of infectious and
noninfectious inflammation, and has proven to contribute to the
diagnosis in patients with fever of unknown origin or bloodstream
infections.3,4,30 In a retrospective study of 40 patients with
bloodstream infection and a high risk of complications, FDG-PET
was used to diagnose a clinically relevant new focus in 45% of
cases, while, on average, 4 conventional diagnostic tests had al-
ready been performed previously. To our knowledge, at this time
there are no guidelines describing a diagnostic protocol for the
detection of metastatic infectious foci in patients with Gram-
positive bacteremia, except for the recommendation to perform
echocardiography in patients with S. aureus bacteremia.
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Here we present a prospective study in patients with S.
aureus or Streptococcus species bacteremia with at least 1 risk
factor for the development of metastatic foci. Based on pre-
vious studies, FDG-PET/CT was routinely added to the diag-
nostic workup including echocardiography. We evaluated the
outcome and contribution of all diagnostic procedures, identi-
fied risk factors for developing metastatic infection, and assessed
the relation between the presence of metastatic infection and
clinical outcome.
PATIENTS AND METHODS
Patients
The current study was part of a prospective matched case-
control study evaluating the utility of FDG-PET/CT for the de-
tection of metastatic infectious foci in high-risk patients with
Gram-positive bacteremia (International Standard Randomised
Controlled Trial Number [ISRCTN] 76425553). From November
2005 until January 2008, patients were recruited from the Rad-
boud University Nijmegen Medical Center, a 950-bed university
hospital. Charts of all subsequent adult patients were reviewed
within the first working day after a blood culture showed growth
of S. aureus or Streptococcus species (excluding S. pneumoniae).
Patients were eligible when a systemic inflammatory response
syndrome was present at the time the blood culture was taken.1 In
addition, at least 1 of the known risk factors for the development
of complicating infection had to be present, that is, community
acquisition, signs of infection 948 hours before initiation of
appropriate treatment (treatment delay), fever 972 hours after
initiation of appropriate treatment, or positive blood cultures
948 hours after initiation of appropriate treatment. Patients with
chemotherapy-induced neutropenia and pregnant women were
excluded. The study was approved by the local ethics committee.
Written informed consent was obtained from all patients.
Clinical Features
The portal of entry was defined as a localized site of in-
fection preceding bacteremia. A central venous catheter was con-
sidered a portal of entry if there was evidence of inflammation at
the insertion site or if culture of the catheter tip grew the same
microorganism as the blood culture in the absence of evidence
for another source of infection. Respiratory or urinary tract in-
fections were diagnosed as portal of entry only when specific
symptoms and signs were present in addition to positive culture
results. Phlebitis due to peripheral intravascular catheters and
cellulitis, categorized as skin infections, were considered as por-
tals of entry, if present.
Bacteremia was defined to be nosocomial if only blood
cultures taken after 948 hours of hospitalization were positive
and clinical signs of the infection were absent at the time of
admission. All other infections were considered community ac-
quired. Both infectious foci without anatomic relation to the portal
of entry and direct extension of the infection beyond the primary
focus of infection were defined as complicating infectious foci.
Endocarditis was defined according to the Duke criteria.23 Pred-
nisone Q10 mg, or its equivalent dose of corticosteroids, was
considered immunosuppressive treatment.
Metastatic infectious foci that were not diagnosed during
the first period of infection, or a second period of bacteremia
with the same microorganism, both within 3 months of the first
positive blood culture, were defined as relapse of infection.
Patients were considered cured if no symptoms or signs of in-
fection were present 3 months after discontinuation of antibi-
otic treatment.
Diagnostic Workup
All patients were visited by an infectious diseases specialist
for physical examination. Echocardiography was recommended.
Transthoracic echocardiography (TTE) was used as a first-line
screening technique, except for those patients with prosthetic
valves, in whom transesophageal echocardiography (TEE) was
the first-line technique. TEE was advocated in all patients in
whom TTE was unremarkable, especially when imaging was
hampered due to technical or anatomical problems. FGD-PET/
CTwas performed within 2 weeks after the first positive blood
culture in all patients who gave written informed consent. Fur-
ther diagnostic procedures like ultrasound, CT, and magnetic
resonance imaging (MRI) were requested only in the presence of
guiding signs or symptoms, or for confirmation of FDG-PET/CT
findings. For treatment monitoring, C-reactive protein (CRP) and
leukocyte counts were performed twice weekly. Blood culture
samples were taken daily until 3 days after appropriate treatment
had started and continued every other day as long as blood cul-
ture results remained positive.
Diagnosis and Patient Follow-Up
Patient follow-up ended 6 months after the first positive
blood culture. Standard duration of antibiotic treatment in patients
with uncomplicated bacteremia was 14 days. Treatment duration
was extended to 6Y12 weeks in case of infectious complications,
depending on the localization and guidelines. Endocarditis was
treated according to American Heart Association guidelines.5
The final diagnosis was established by the attending physician
and the first and last author (FJV and CPBR). The presence
of metastatic infectious foci was based on the combination
of clinical findings and results of conventional radiologic tech-
niques. Wherever possible, samples were taken for culture and/
or pathology and served as final proof. Because FDG-PET/CT
is not an established imaging technique for some types of in-
fectious foci that were diagnosed, a final diagnosis was never
based on FDG-PET/CT findings alone.
Data Collection and Statistical Analysis
All epidemiologic data as well as diagnostic procedures and
treatment data were collected in a structured database (Microsoft
Access). Descriptive statistics for continuous variables are pre-
sented as means T standard deviations. Differences between
groups were tested with unpaired Student t-tests for continuous
variables and with Fisher exact tests for categorical variables.
Differences were considered to be statistically significant at p G
0.05. Sensitivity and specificity were calculated with 95%
confidence intervals (CIs). A parameter was considered to be a
significant predicting factor when the 95% CI of the relative
risk was 91.
RESULTS
A total of 177 patients with either S. aureus or Streptococcus
species bacteremia were identified during the study period. Of
these patients, 53 had none of the predefined risk factors for
the presence of metastatic infection. Nine patients refused in-
formed consent, and 115 patients were included in the study (85
S. aureus, 13 hemolytic streptococci, 17 viridans streptococci).
Most infections (72%) were community acquired (Table 1). Char-
acteristics of patients with S. aureus or Streptococcus species dif-
fered in several aspects. Compared to the Streptococcus group,
patients in the S. aureus group were more often primarily admitted
to the intensive care unit (24% vs. 0%, p = 0.02), blood cultures
remained positive for 948 hours after initiation of therapy more
often (25% vs. 7%, p = 0.03), and significantly more patients
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suffered from persistent fever 972 hours after the start of ther-
apy (61% vs. 33%). The portal of entry was unknown in more
than half of all patients (61/115, 53%), significantly more often
in patients with Streptococcus species bacteremia than S. aureus
bacteremia (70% vs. 47%, p = 0.04) (Table 2). Skin infections
were most often diagnosed as the portal of entry, especially in
patients with S. aureus bacteremia.
Metastatic infectious foci were detected in 84 of 115 (73%)
patients (Table 3). The portal of entry was known in only 38%
of patients, and an unknown portal of entry was a significant
risk factor for developing metastatic foci (odds ratio, 5.6; 95%
CI, 2.3Y13.8). Mean CRP levels on admission were significantly
higher in patients with metastatic infectious foci: 74 (95% CI,
45Y103 mg/mL) vs. 160 mg/mL (95% CI, 132Y188 mg/mL), p G
0.01. The maximal CRP levels during admission did not dif-
fer significantly between the 2 groups: 172 mg/mL (95% CI,
127Y217mg/mL) vs. 224mg/mL (95%CI, 197Y251mg/mL), p =
0.53). Treatment delay of 948 hours was a strong predictor for
developing metastatic infectious foci (p G 0.01). In total, 131 me-
tastatic infectious foci were diagnosed in 84 patients (Table 4).
The incidence of metastatic infection was similar in patients with
Streptococcus species and patients with S. aureus bacteremia.
Endocarditis, endovascular infections, pulmonary abscesses, and
spondylodiscitis were diagnosed most frequently (see Table 4)
(Figure 1). Pulmonary foci were found significantly more
often in patients with S. aureus bacteremia than in those with
Streptococcus species bacteremia (p = 0.01). In 30 (26%) pa-
tients, more than 1 complicating focus of infection was present.
In 13 of 22 (59%) patients with endocarditis, another metastatic
focus of infection was detected (Figure 2). All 22 endocarditis
cases were proven according to the Duke criteria.23 Symptoms
guiding the attending physician in the diagnostic workup were
present in only a minority of cases (41%). Fifty-six foci were
diagnosed by either culture or pathology results. The remaining
53 foci were diagnosed using a combination of clinical exami-
nation and conventional radiologic techniques.
FDG-PET was performed in 102 patients, echocardiogra-
phy in 85, CT in 60, ultrasound in 56, and MRI in 20 patients
(Table 5). FDG-PET was the first to localize metastatic infec-
tious foci in 35 of 115 (30%) patients, most of whom had no
guiding symptoms. In 4 patients FDG-PET was false positive,
resulting in a positive predictive value of 96%. In 1 patient with
TABLE 1. Baseline Characteristics of High-Risk Patients With Gram-Positive Bacteremia
Characteristic
All Patients Staphylococcus aureus Streptococcus spp.
P
(n = 115) (n = 85) (n = 30)
No. (%) No. (%) No. (%)
Mean age, yr (T SD) 59 T 15 59 T 15 59 T 15
Male 67 (58) 52 (61) 15 (50) 0.29
Community acquisition 83 (72) 58 (68) 25 (83) 0.15
Primary ICU admission 20 (17) 20 (24) 0 (0) 0.02
Treatment delay 948 h* 83 (72) 59 (69) 24 (80) 0.35
Positive blood cultures 948 h after treatment 23 (20) 21 (25) 2 (7) 0.03
Fever 972 h 62 (54) 52 (61) 10 (33) 0.01
CVC present on admission 12 (10) 6 (7) 6 (20) 0.08
Diabetes mellitus 29 (25) 21 (25) 8 (27) 0.81
Malignancy 14 (12) 11 (13) 3 (10) 1.0
Immunosuppression 22 (19) 17 (20) 5 (17) 0.79
Dialysis 4 (3) 3 (4) 1 (3) 1.0
Alcohol abuse 6 (5) 4 (5) 2 (7) 0.65
Joint prosthesis 16 (14) 14 (16) 2 (7) 0.23
Cardiac valve prosthesis 9 (8) 7 (8) 2 (7) 1.0
Vascular prosthesis 14 (12) 11 (13) 3 (10) 1.0
Pacemaker 7 (6) 4 (5) 3 (10) 0.38
Abbreviations: ICU = intensive care unit, CVC = central venous catheter.
*Delay between first clinical signs of infection and initiation of treatment.
TABLE 2. Portal of Entry of Bacteremia
Portal of
Entry
All
Patients
Staphylococcus
aureus
Streptococcus
spp.
P
(n = 115) (n = 85) (n = 30)
No. (%) No. (%) No. (%)
Unknown 61 (53) 40 (47) 21 (70) 0.04
Known 54 (47) 45 (53) 9 (30)
CVC 7 4 3 0.37
Skin
infection
16 14 2 0.23
Pulmonary
infection
5 5 0 0.32
Urinary tract
infection
4 4 0 0.57
Wound
infection
11 10 1 0.59
Other* 11 8 3 1.0
Abbreviations: CVC = central venous catheter.
*Other = manipulation urinary tract (2), colitis (2), endometritis (2),
cholangitis, puncture carinal nodes, steroid injection bursa trochanterica,
known fistula osteomyelitis, meningitis.
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endocarditis, abnormal uptake in the right shoulder was due to
tendinitis. Abnormal FDG-uptake was caused by a sterile hem-
orrhage in the psoas muscle during anticoagulant use in a second
patient. False-positive uptake in the colonic wall was seen in 1
patient, and 1 patient died before further investigations could
be performed to confirm abnormal pleural FDG-uptake. She
had possible endocarditis and pleural effusion with persistently
positive blood cultures. The negative predictive value was 98%
when only those foci situated inside the area scanned by FDG-
PETwere counted (see Table 5). In 1 patient, a pacemaker lead
infection was missed by FDG-PET. Another 10 foci were not
revealed; however, these foci were situated in the central nervous
system in 5 patients, and in the distal extremities in the other 5
patients. These areas are not captured by routine PET scanning.
In all 10 patients in whom FDG-PET did not reveal metastatic
infectious foci, guiding signs and symptoms directed the at-
tending physician to perform further investigations.
Routine echocardiography, performed in 86 patients, sup-
ported the presence of endocarditis in 22 (26%) cases. TTE was
performed in 77 patients, with 43 followed by TEE. A primary
TABLE 4. Localization of Metastatic Infectious Foci and Presence of Guiding Signs and Symptoms
Localization
All Patients
Guiding Signs and
Symptoms No.
Staphylococcus aureus Streptococcus spp.
P
(n = 115) (n = 85) (n = 30)
No. (%) No. (%) No. (%)
Not present, no. of patients 31 (27) 21 (25) 10 (33)
Present, no. of patients 84 (73) 64 (75) 20 (67) 0.47
Endocarditis 22 0 13 9 0.1
Endovascular* 19 5 11 8 0.09
Lung 16 5 16 0 0.01
Liver 2 1 1 1 0.46
Spleen 3 0 3 0 0.57
Joint 9 8 8 1 0.44
Osteomyelitis 6 4 5 1 1.0
Spondylodiscitis 11 8 10 1 0.28
Psoas 4 1 3 1 1.0
Soft tissue 11 6 11 0 0.06
Central nervous system 11 11 8 3 1.0
Eye 3 3 1 2 0.17
Prosthetic joint 10 8 8 2 1.0
Intraabdominal 3 1 2 1 1.0
Kidney 1 1 1 0 1.0
Total number of metastatic foci 131 54 101 30
*Bentall prosthesis aortic arch (2), aortic prosthesis (3), mycotic aneurism aorta (3), mycotic aneurism femoral artery (2), subclavian vein after line
removal (4), pacemaker lead (1), mycotic aneurism iliac artery (1), septic thrombophlebitis femoral vein (2), pylephlebitis (1).
TABLE 3. Possible Risk Factors for the Presence of Metastatic Infectious Foci
Risk Factor
Metastatic Focus Metastatic Focus
Present Absent
(n = 84) (n = 31) Odds Ratio
No. (%) No. (%) P (95% CI)
Community acquisition 63 (75) 20 (65) 0.35 1.6 (0.6Y4.0)
Treatment delay 948 h 68 (81) 14 (45) G0.01 5.6 (2.3Y13.8)
Blood cultures 948 h 20 (24) 3 (10) 0.12 2.9 (0.8Y10.6)
Fever 972 h 50 (60) 12 (39) 0.06 2.3 (1.0Y5.4)
CVC present on admission 6 (7) 6 (19) 0.08 0.3 (0.1Y1.1)
Portal of entry unknown 52 (62) 9 (29) 0.03 4.0 (1.6Y9.7)
Diabetes mellitus 22 (26) 7 (23) 0.81 1.22 (0.5Y3.2)
Malignancy 8 (10) 6 (19) 0.2 0.4 (0.1Y1.4)
Immunosuppression 16 (19) 6 (19) 1.0 1.0 (0.4Y2.8)
Alcoholism 3 (4) 3 (10) 0.34 0.4 (0.1Y1.8)
Foreign body material 31 (37) 5 (16) 0.04 3.0 (1.1Y8.7)
S. aureus 64 (76) 21 (68) 0.47 1.5 (0.6Y3.7)
Age 960 yr 47 (56) 18 (58) 0.83 1.1 (0.5Y2.6)
Abbreviations: CVC = central venous catheter.
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TEEwas performed in 9 patients. Sign and symptom-guided CT,
ultrasound, and MRI reached excellent specificity and positive
predictive values with high sensitivity and negative predictive
values (see Table 5). As only a minority of foci were accom-
panied by guiding signs and symptoms, the number of foci
revealed by CT, ultrasound, and MRI remained low.
Risk factors for mortality are listed in Table 6. Persistently
positive blood cultures 948 hours after starting treatment, nos-
ocomial infection, and age above 60 years were associated
with increased mortality. Treatment delay was not associated
with mortality. Median duration of treatment differed signifi-
cantly between patients with or without metastatic infectious
foci (44 vs. 15 d, respectively) (Table 7). Mortality tended to
be lower in patients without complicated infection (25% vs.
16%), albeit not significantly.
Five of 31 patients without proven metastatic foci died
(16%). In retrospect, of these 5 patients, 3 likely had metastatic
foci that could not be diagnosed during life. The first patient had
a possible endocarditis (persistently positive blood cultures, con-
tinuing fever, Janeway lesions, and changed systolic murmur).
He died before echocardiography was performed. The second
patient had persistently positive blood cultures during 72 hours
despite high-dose flucloxacillin and persistent pyuria growing
S. aureus. This patient refused any further investigations. Anti-
biotic treatment was stopped on his request after 15 days. He died
2 weeks after discharge in a nursing home having documented
high fevers during the weeks before his death. The third patient
had positive blood cultures with S. aureus and splinter hemor-
rhages 3 days after a pacemaker implantation. Only TTE was
performed, which did not reveal any signs of endocarditis or
pacemaker lead infection. TEE was refused by the patient, and
the pacemaker was not removed. This patient died while on an-
tibiotic treatment 36 days after admission due to cardiac failure.
Autopsy was refused. If these 3 patients are presumed to have
had metastatic foci, then only 2 patients died in the absence
of metastatic infectious foci. One of these patients died on day 2
because of septic shock, and the other patient died on day 24
after admission with end-stage laryngeal carcinoma.
DISCUSSION
In the current prospective cohort study, the vast majority
of high-risk patients with Gram-positive bacteremia developed
metastatic infectious foci (73%), of which more than 40% were
clinically silent. Mortality rates might be decreased by an active
search for and treatment of clinically silent foci, as mortality
tended to be higher in the presence of metastatic infectious foci.
Earlier studies, which did not specifically address high-
risk patients, have reported an incidence of metastatic foci
ranging from 16% to 36% (Table 8).7,17,20,21,26,27 Patients in the
current study were selected based on the presence of 4 well-
known clinical risk factors for the development of complicated
FIGURE 1. A 65-year-old man with Staphylococcus aureus bacteremia and persistent fever despite antibiotic therapy. Top to bottom,
FDG-PET, CT, and fusion; left, transverse; right, sagittal slices. FDG-PET/CT shows abnormal FDG uptake (arrows) compatible with
C6-7 spondylodiscitis and spreading inside the spinal canal compatible with an epidural abscess. The latter was confirmed on
CT myelography. MRI was not possible due to the patient’s intracardial defibrillator. [This figure can be viewed in color online at
http://www.md-journal.com.]
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infection.9,10,21,24 These differences in patient characteristics may
hamper a direct comparison between studies, but the active search
in the current study aimed at early identification of metastatic
foci most likely contributed to the much higher yield of meta-
static infections. The active approach using FDG-PET/CT and
echocardiography in the first 2 weeks of admission in high-risk
patients with Gram-positive bacteremia revealed significantly
more metastatic foci compared to a matched control group in
whom the diagnostic regimen was symptom guided and led to
significantly lower mortality rates.30 Three earlier studies have
reported that significantly fewer metastatic foci could be diag-
nosed in patients in whom recommendations of an infectious
disease specialist were not followed.8,15,26 Most importantly, this
was due to the failure to perform supplementary investigations
such as echocardiography and surveillance blood cultures.
Positive blood cultures during follow-up after the start of
antimicrobial therapy have been found to be a predictor of me-
tastatic infectious disease.22 In the present study we identified
delayed initiation of treatment, the presence of foreign body
material, and an unknown portal of entry for infection as risk
factors for the development of metastatic foci. Of patients with
an unknown portal of entry, 52 of 61 (82%) developed proven
FIGURE 2. Mycotic aneurysm of the a. femoralis profunda in a 49-year-old man with Staphylococcus aureus bacteremia and endocarditis.
Top to bottom, FDG-PET, CT, and fusion; left, coronal; right, transverse slices. FDG-PET/CT shows abnormal FDG uptake (arrows)
compatible with vascular infection. [This figure can be viewed in color online at http://www.md-journal.com.]
TABLE 5. Diagnostic Utility of Imaging Techniques Contributing to Diagnosis of Metastatic Infectious Foci
Technique No. of Examinations Contributory No. (%) Sensitivity % Specificity % PPV % NPV %
FDG-PET 102 61 (60) 99 92 96 98
CT scan* 60 32 (53) 94 100 100 93
Ultrasound* 56 19 (34) 95 100 100 96
MRI* 20 12 (60) 92 100 100 88
*CT, ultrasound, and MRI were performed only in case of guiding signs or symptoms and when suitable for the area to be investigated: chest CT in
21, abdominal CT in 24, central nervous system (CNS) CT in 11, soft tissue CT in 4, abdominal ultrasound in 30, soft tissue ultrasound in 25, CNSMRI
in 13, and soft tissue MRI in 8 patients. FDG-PETwas the only diagnostic technique routinely performed for screening purposes.
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metastatic infection, versus 32 of 54 (59%) patients admitted
with a known portal of entry. CRP levels on admission tended
to be higher in patients with metastatic foci; however, the
maximal CRP level during admission did not differ between
patient groups. Most likely, the CRP level on admission reflects
the duration of illness on admission and therefore is a surrogate
marker for treatment delay. As some overlap in CRP levels on
admission was found between groups with and without meta-
static infectious foci, CRP levels should be interpreted only in
relation to the patient’s history, for example regarding treatment
delay, which probably leads to a higher CRP upon admission.
It is important to realize that only 41% of metastatic foci
were associated with clear signs or symptoms guiding the phy-
sician to a diagnosis. Especially deep soft tissue infections, en-
dovascular, and pulmonary foci lacked guiding symptoms. When
ordered based on symptoms, CT, MRI, and ultrasound have high
predictive values. However, as only a minority of patients had
guiding signs or symptoms, only a minority of foci (9%Y24%)
could be identified using CT, MRI, and ultrasound. In contrast,
routinely performed FDG-PET revealed 69% of all metasta-
tic infectious foci that were identified. In approximately 30% of
patients, FDG-PET/CT revealed at least 1 clinically silent in-
fectious metastatic focus. This is in accord with studies on fever
of unknown origin, in which whole body FDG-PET proved to be
superior when compared to routinely performed combined chest
and abdominal CT.3,6 In a retrospective study on the detection
of metastatic foci, FDG-PET revealed a significant number
of new relevant foci even after a total of 4 conventional im-
aging techniques had been performed.2 The superiority of FDG-
PET/CT is not only due to whole body imaging, but also
because FDG-PET provides functional information in contrast
to CT, and, to a lesser extent, to MRI. Previously, FDG-PETalso
proved to be superior in postoperative wound infections
and vascular graft infections when compared to CT scanning,
and in spondylodiscitis when compared to MRI.11,13,19,25,31 The
most important technical drawback in FDG-PET compared to
CTandMRI is the lower spatial resolution (3-5 mm compared to
1Y2 mm). In suspected epidural extension accompanying
spondylodiscitis, MRI might be contributory. CT, ultrasound,
and MRI therefore are not suitable as a screening technique to
detect metastatic infectious foci in patients with a high proba-
bility of having these infectious complications, because only a
limited part of the body is scanned.12 Routine echocardiography
revealed vegetations in approximately one-quarter of patients
who underwent echocardiography.
Mortality rates in patients with Gram-positive bacteremia
are high. We speculated that a more rigorous search for meta-
static infection could influence outcome by decreasing relapse
rates and mortality rates, and this has indeed been confirmed
in our prospective matched case-control study,30 in which the
diagnostic work-up was symptom guided and only routine
echocardiography was advocated, according to guidelines.5
Compared with rates of the control group in that study, relapse
rates in patients with S. aureus bacteremia were significantly
lower in the study group (8.9% vs. 1.4%, p = 0.04), as was
mortality (30% vs. 19%, p G 0.01). This underscores that
appropriate and early diagnosis of metastatic infectious foci is
important for adequate treatment of these patients, for example
by timely initiation of antibiotic treatment, prolongation of anti-
biotic treatment, or drainage of abscesses. The extra costs related
to treating the increased number of metastatic infectious foci in
high-risk patients are balanced by the reduction of re-admissions
due to relapse of infection or protracted cure.30a To our knowl-
edge, at this time there are no guidelines describing a diagnostic
protocol for the detection of metastatic infectious foci in patients
with Gram-positive bacteremia, except for the recommendation
to perform echocardiography in patients with S. aureus bacter-
emia. It has been shown before that metastatic infectious foci can
be detected in most parts of the body by FDG-PET scanning, and
therefore FDG-PET was included on a routine basis in the di-
agnostic protocol of our study.3,30
Earlier studies in patients with Gram-positive bacteremia
have also reported high mortality rates, especially in patients
with S. aureus bacteremia, varying between 9% and
38%.8,9,17,20,26,27 Only sparse information on mortality rates
among patients with streptococcal bacteremia is available. In
patients with bacteremia due to hemolytic group A and G strep-
tococci, mortality rates varied between 14% and 23%.2,14 In a
TABLE 6. Risk Factors for Mortality at 6 Month Follow-Up
Risk Factor
Survivors Died
P
(n = 89) (n = 26)
No. (%) No. (%)
Community acquisition 69 (78) 14 (54) 0.03
Treatment delay 948 h 63 (71) 20 (77) 0.63
Positive blood cultures 948 h 14 (16) 9 (35) 0.05
Fever 972 h 47 (53) 15 (58) 0.82
CVC present on admission 9 (10) 3 (12) 1.0
Portal of entry unknown 44 (49) 10 (38) 0.38
Diabetes mellitus 19 (21) 10 (38) 0.12
Malignancy 11 (12) 3 (12) 1.0
Immunosuppression 13 (14) 9 (35) 0.43
Alcoholism 5 (6) 1 (4) 1.0
Foreign body material 26 (29) 10 (38) 0.47
S. aureus 63 (71) 23 (88) 0.08
Age 960 yr 44 (49) 21 (81) G0.01
Abbreviations: CVC = central venous catheter.
TABLE 7. Patient Outcomes at 6 Month Follow-Up
Outcome
Total Metastatic Foci
Staphylococcus aureus
Metastatic Foci
Streptococcus spp.
Metastatic Foci
Present Absent Present Absent Present Absent
(n = 84) (n = 31) (n = 64) (n = 21) (n = 20) (n = 10)
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Median treatment duration (d) 44 15 42 15 48 13
Mortality 21 (25) 5 (16) 19 (30) 4 (19) 2 (10) 1 (10)
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recent series of 53 patients with Streptococcus species bacter-
emia, mortality was 11%.7
In the present study among patients with Gram-positive
bacteremia, persistently positive blood cultures and older agewere
associated with increased mortality rates, as were nosocomial
infections. In contrast to other studies, treatment delay and com-
munity acquisition were not associated with increased mortal-
ity. Two possible explanations come to mind. First, patients were
selected using a set of 4 known clinical parameters predicting
complicated infection, among which treatment delay and com-
munity acquisition both were present in approximately 75% of
patients. The study therefore was not designed to identify risk
factors for complicated outcome. Treatment delay, on the other
hand, was a strong predictor for the presence of metastatic in-
fectious foci, which were treated accordingly, and death might
have been prevented. Since an intensive search for the presence
of metastatic foci was performed, it is possible that no relation
between treatment delay and mortality was found. Lautens-
chlager already reported that complicated infection was associ-
ated with increased mortality rates, which has been confirmed in
other studies.8,17,20 In these studies, complicated infection was
defined as a combination of metastatic foci of infection, relapse,
or the inability to remove the primary focus of infection. An
important explanation for treatment failure in these studies was
the delayed start of appropriate treatment in patients without
an identifiable focus of infection. In a retrospective survey of
281 patients with S. aureus bacteremia, bacteremia was judged
insignificant in 19% until a metastatic focus of infection was
detected.20 Treatment delay for more than 45 hours was asso-
ciated with increased mortality in a retrospective cohort of 167
patients with hospital-acquired S. aureus bacteremia.24 Finally,
inappropriate focus eradication has been associated with relapse
of infection and mortality in other studies.7,17 These studies
suggest that identifying metastatic foci of infection may be an
important tool to improve treatment outcome in patients with
Gram-positive bacteremia.
In conclusion, the present study has demonstrated 2 im-
portant issues: first, after an intensive search aimed at detect-
ing metastatic infectious foci, the majority of high-risk patients
with Gram-positive bacteremia did have metastatic foci. Second,
the majority of these metastatic foci did not have guiding signs
or symptoms, which can lead to incomplete focus eradica-
tion. Thus in patients with Gram-positive bacteremia and a high
risk for developing complicated infection (community acquisi-
tion, treatment delay, persistently positive blood cultures 948 h,
and persistent fever 972 h after initiation of treatment), a
structured protocol including echocardiography and FDG-PET
aimed at detecting metastatic infectious foci may contribute to
improved outcome.
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